Tuesday, October 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

What Is the Jevons Paradox and What Does It Mean for Micron and Sandisk Investors After Google's Revolutionary AI Breakthrough?

View original at nasdaq.com
What Is the Jevons Paradox and What Does It Mean for Micron and Sandisk Investors After Google's Revolutionary AI Breakthrough? Key Points Google's memory-compression algorithm caused Micron and Sandisk stocks to plunge…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q3 revenue forecast of $33.5 billion, representing growth of 260% year over year and 40% quarter over quarter

    60% confidence
  • Gross margin expected to reach 65.9% at midpoint, nearly triple last year's 22.5%

    60% confidence
  • More efficient use of resources reduces their costs, ultimately increasing demand for them

    60% confidence
  • TurboQuant will enable larger LLMs, faster inference and better tokenomics, spurring more spending

    60% confidence
  • Stock Advisor's total average return is 926%, outperforming the S&P 500's 185%

    60% confidence
  • Adjusted diluted earnings per share expected to reach roughly $19.15, a 10-fold increase

    60% confidence
  • Gross margin expected to increase by 660 basis points, from 74.4% to about 81%

    60% confidence
  • Reiterated outperform (buy) ratings on both Micron and Sandisk

    60% confidence
  • Q3 revenue forecast of $4.6 billion at midpoint of guidance, representing 171% growth

    60% confidence
  • TurboQuant reduces memory usage by at least 6x and delivers up to 8x speedup, all with zero accuracy loss, redefining AI efficiency

    60% confidence
  • 10 best stocks for investors to buy now identified, and Alphabet wasn't one of them

    60% confidence
  • Developments like TurboQuant are positive, as performance improvements will drive further adoption of AI and strengthen demand for key components such as memory chips

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com